CC genotype. In spontaneous resolvers and inactive carriers, IL28B CC did not correlate with the magnitude of T-cell responses. Conclusions: In OBI donors, IL28B CC correlates with the intensity of HBV-specific T-cell responses. In this study, IL28B CC is not statistically associated with OBI or with HBV clearance, but a larger number of cases is needed before completely ruling out its role in HBV infection.
Introduction
Hepatitis B virus (HBV) is a noncytopathic DNA virus that causes acute and chronic hepatitis [1, 2] . Occult HBV infection (OBI) is characterized by the presence of HBV DNA in liver tissue or serum (<200 IU/ml) of individuals testing negative for hepatitis B surface antigen (HBsAg), with or without other HBV serological markers [3] .
HBV-induced liver injury and viral clearance are mediated by the host's immune responses [4] . In acute HBV infection, a cytotoxic T-lymphocyte response to HBV proteins is observed in patients who successfully clear the virus [4] [5] [6] . Increased hepatitis B core (HBcAg)-and envelope (HBeAg)-specific T-helper cell responses are also seen in patients with viral elimination [7] . In contrast, chronic HBV infection is characterized by an inefficient
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Abstract
Aims:
To investigate the influence of IL28B polymorphism in occult hepatitis B infection (OBI) and whether IL28B genetic variants are associated with hepatitis B virus (HBV)-specific T-cell responses. Patients and Methods: The rs12979860 IL28B genotype was determined in 34 OBI blood donors, 22 spontaneous HBV resolvers, 36 inactive HBV carriers and 25 seronegative donors. T-cell responses to HBV recombinant proteins were assessed by interferon-γ enzyme-linked immunospot assay. Results: The frequency of the IL28B CC genotype among OBI patients was similar to that of inactive carriers [41 vs. 39%, respectively, p = 0.961; odds ratio (OR) = 1.10; 95% confidence interval (CI) = 0.42-2.86; p = 0.845]. The IL28B CC genotype was found more frequently in spontaneous resolvers, although the differences were not significant (45 vs. 39%, spontaneous resolvers and inactive carriers, respectively; p = 0.828; OR = 1.31; 95% CI = 0.45-3.83; p = 0.622). HBV-specific T-cell responses were detected in OBIs, and significantly stronger T-cell responses towards hepatitis B envelope antigen were observed in those with the IL28B immune response to HBsAg and weak but demonstrable responses to polymerase, HBcAg and HBeAg [4, 5, 8] . Recently, we observed that the HBV-specific T-cell response in individuals with occult HBV is comparable to the response in resolved HBV infection and has the capability to suppress viral replication to low viral loads and HBsAg expression to undetectable levels [9] .
Genome-wide association studies have shown that single nucleotide polymorphisms (SNPs) within or outside the IL28B (rs12979860) gene coding for IFN-λ 3 strongly associate with both spontaneous and treatmentinduced resolution of HCV infection [10] [11] [12] [13] [14] [15] . Although the mechanism remains unclear, IFN-λ 3 inhibits viral replication, and some studies suggest that it may modulate innate and adaptive immune responses [16, 17] . Although several studies have not observed a correlation between the IL28B genotype and spontaneous clearance or resolution with pegylated interferon-α treatment in HBV infection [18] [19] [20] [21] , there are no studies which investigated whether the IL28B genotype could be determinant in OBI infection.
The aims of this study were to determine whether variations at the SNP rs12979860 correlate with OBI infection in a cohort of Spanish blood donors and the extent to which rs12979860 variants correlate with the magnitude of the HBV-specific CD4+ and CD8+ T-cell response.
Patients and Methods
Study Groups
A subset of 34 OBI blood donors was enrolled for the determination of the IL28B rs12979860 genotype and the HBV-specific T-cell immune response. OBI donors were identified during routine screening in the Blood Bank Center of Catalonia (Spain) from January 2006 to December 2008. Because liver biopsy was absent in these subjects, the definition of OBI was adapted and established as HBsAg-negative, anti-HBc-positive (anti-HBc IgM-negative) and anti-HBs-positive or -negative testing, with HBV DNA <200 IU/ml in serum [3] . The comparison populations were 22 donors with spontaneously resolved HBV, 36 inactive HBV carriers and 25 HBV-seronegative donors. The characteristics of the study subjects are shown in table 1 . The study was approved by the Institutional Review Board on Clinical Research. None of the donors included in the study presented a coinfection with HCV and/or HIV.
Serological Tests
All blood donations were tested individually for HBV DNA by the transcription-mediated amplification system (Procleix Ultrio Assay, Novartis, Emeryville, Calif., USA; detection limit 10 IU/ml; positive hit rate 95%). Specimens initially reactive were confirmed by HBV DNA proteinase K extraction and real-time PCR according to a previously published protocol [22] . Donations were screened for HBsAg with a commercial chemiluminescent immunoassay (Prism, Abbott Diagnostics, Wiesbaden, Germany). In samples confirmed to be reactive to HBsAg and/or HBV DNA, antibodies to core (total anti-HBc, anti-HBc IgM) and anti-HBs were determined (Architect, Abbott Diagnostics).
In HBV DNA-positive donations, the HBV genotype was determined using a commercial line probe assay (INNO-LIPA HBV Kit, Innogenetics, Belgium).
IL28B
Genotyping DNA was extracted from 5-10 × 10 6 peripheral blood mononuclear cells (PBMCs) using a QIAamp DNA Blood Minikit (Qiagen, Hilden, Germany). IL28B rs12979860 genotyping was performed using real-time PCR based on TaqMan technology (Applied Biosystems, Foster City, Calif., USA) [23] . The primers used were 5 ′ -GCCTGTCGTGTACTGAACCA-3 ′ (forward) and 5 ′ -GCGCGGAGTGCAATTCAAC-3 ′ (reverse), and the TaqMan MGB probe sequences were 5 ′ -TGGTTCGCGCCTTC-3 ′ and 5 ′ -CTGGTTCACGCCTTC-3 ′ . The probes were labeled with fluorescent dyes VIC and FAM, respectively. PCR was carried out in a total of 25 μl, and the thermal cycling profile was as follows: incubation for 2 min at 50 ° , followed by a denaturation step at 95 ° for 10 min, and 40 cycles at 95 ° for 1 min, 60 ° for 1 min. Genotyping of each sample was analyzed by the SDS software (Applied Biosystems).
HBV Antigens
Purified recombinant HBV antigens (HBsAg A2 genotype, HBcAg and HBeAg) were purchased from Prospec (Rehovot, Israel). Recombinant HBsAg A2 was expressed in the yeast Pichia pastoris, and HBcAg and HBeAg were expressed in Escherichia coli and used at 2 μg/ml as previously described [15] . Antigen purity was >95% for HBsAg A2 and HBeAg, and >90% for HBcAg.
Interferon-γ Enzyme-Linked Immunospot Assay
Cryopreserved PBMCs were used in all studies. Duplicates of thawed PBMCs were tested by IFN-γ enzyme-linked immunospot (ELISpot) assay as previously reported [15] . Results were expressed as number of IFN-γ spot-forming cells (SFCs) per 10 6 PBMCs. Assays with high background (mean 10 SFCs/well in buffer control wells) or no phytohemagglutinin responses were excluded.
Statistical Analysis
Fisher's exact test or χ 2 and Student's t tests were used for statistical comparison of rates and of means of normally distributed quantitative measures, respectively. Results are expressed as odds ratios (ORs) with 95% confidence intervals (CIs) [24] . Medians of IFN-γ SFCs among groups were compared with a nonparametric Mann-Whitney U test. p values of less than 0.05 were considered significant. All calculations were performed with SPSS software 15.0 (SPSS Inc., Chicago, Ill., USA).
Results
The frequency of the CC genotype at the SNP rs12979860 among OBI blood donors was similar to that of inactive HBV carriers (41 vs. 39%, respectively, p = Similarly, the IL28B CC genotype was found more frequently in donors who spontaneously resolved HBV infection, although the differences were not significant (45 vs. 39%, spontaneous resolvers and inactive carriers, respectively, p = 0.828; OR = 1.31; 95% CI = 0.45-3.83; p = 0.622).
To determine the intensity of the HBV immune response, we determined the median number of SFCs to different HBV antigens and compared them between study groups. The median IFN-γ SFCs/10 6 PBMCs for HBsAg was 300 in the OBI group, a value higher than that seen in inactive carriers (300 vs. 140, p = 0.011). For HBcAg, OBI donors presented a median of 285 IFN-γ SFCs/10 6 PBMCs; again, this was higher than that of inactive carriers (285 vs. 135, p = 0.021). The same profile was observed for HBeAg (210 OBI vs. 95 inactive carriers, p = 0.003). The magnitude of the IFN-γ response to the 3 HBV antigens used in the ELISpot test did not differ between the OBI patients and donors with spontaneously resolved infection (300 vs. 530, p = 0.174, for HBsAg; 295 vs. 195, p = 0.298, for HBcAg and 210 vs. 120, p = 0.190, for HBeAg, respectively).
To determine whether IL28B genetic variation influences HBV-specific T-cell responses in blood donors with different HBV status, we stratified each study group according to the rs12979860 genotype (CC vs. non-CC). As shown in figure 1 , in spontaneous resolvers and inactive HBV carrier groups, the presence of the IL28B CC genotype did not correlate with the quality (HBV antigen) or magnitude of T-cell responses (number of SFCs; fig. 1 ). In blood donors with spontaneous HBV clearance, the median number of IFN-γ SFCs per 10 6 PBMCs in those with the IL28B CC genotype was similar to that observed in those with the non-CC genotype for all studied antigens (395 vs. 715 for HBsAg, 195 vs. 220 for HBcAg and 120 vs. 150 for HBeAg, in IL28B CC and Figures in parentheses indicate percentages. ALT = Alanine aminotransferase; n.d. = not determined; neg. = negative; pos. = positive; und. = undetectable, i.e. <10 IU/ml. * p < 0.001: significant differences between OBI, inactive carriers and HBV seronegative blood donors. a Detection limit: 0.1 IU/l. b HBV genotype could only be determined by hybridizing in 13 subjects in the OBI group.
IL28B non-CC genotypes, respectively; p = not significant). Similar findings were seen in inactive HBV carriers (165 vs. 140 for HBsAg, 100 vs. 150 for HBcAg and 100 vs. 85 for HBeAg, IL28B CC and IL28B non-CC, respectively; p = not significant; fig. 1 ). Surprisingly in the OBI group, donors with the IL28B CC genotype presented an intensity of IFN-γ responses higher than blood donors with the IL28B non-CC genotype, although the differences were only significant concerning the envelope antigen (360 vs. 230 for HBsAg, 495 vs. 215 for HBcAg and 280 vs. 135 for HBeAg, IL28B CC and IL28B non-CC, respectively; fig. 1 ). The same results were observed when we only considered European blood donors (data not shown).
Discussion
Genome-wide association studies identified several SNPs close to/within the IL28B gene, strongly associated with both spontaneous and IFN-α-treatmentinduced HCV clearance [10] [11] [12] [13] [14] [15] . IL28B (IFN-λ 3 ) triggers a cascade through the JAK-STAT pathway that upregulates the IFN-stimulated genes (ISGs). The effects of IL28B are similar to those of type I IFNs (IFN-α and IFN-β); however, IFN-λ 3 binds to a distinct receptor that may modulate a different set of ISGs [25] . Because IFN-α and ISGs are thought to be important in the immune response to HBV [26, 27] , we can assume that IL28B may also be important in spontaneous HBV clearance and in OBI. A recent study performed in a large Chinese cohort has shown that the IL28B rs12979860 polymorphism was not significantly associated with spontaneous HBV recovery, liver cirrhosis, clearance of HBeAg and HBV DNA levels [28] . However, there are no studies that have investigated whether the IL28B genotype could be determinant in OBI. In our study among Spanish blood donors, we have found that the IL28B CC genotype was not significantly different neither between OBI and inactive carriers (41 vs. 39% rs12979860 CC, respectively, p = 0.961; OR = 1.10) nor between spontaneous HBV recovery and inactive carriers (45 vs. 39% rs12979860 CC, respectively, p = 0.828; OR = 1.31). However, the frequency of IL-28B CC was lower in inactive carriers, therefore a large number of individuals should be studied in order to completely rule out any possible association between IL-28B polymorphisms and HBV infection outcome.
It is not known how rs1298860 affects the function of IL28B, but presumably it alters the immune function towards HCV but not HBV. We also consider that, in addition to inducing ISG expression, IL28B may activate alternative antiviral pathways, such as the adaptive immune response, which may be more important in HCV. This is supported by a study in which IFN-λ 3 , when used as a vaccine adjuvant, significantly increased peripheral blood CD8+ T cells and led to an increase in antigenspecific perforin induction and degranulation [29] . However, in previous studies, we demonstrated that OBI blood donors showed HBV-specific T-cell respons- es which have the capability to suppress the viral replication to low viral loads and HBsAg expression to undetectable levels [9] . In this regard, the findings of the present study that a stronger T-cell response towards HBV antigens, especially HBeAg, was more evident among OBI donors with the CC rs12979860 genotype are intriguing. Although these findings have to be interpreted with caution because of the limited number of individuals, this might suggest that although the IL28B CC genotype is not clearly associated with HBV resolution, it could be determinant to induce more efficient adaptive immune responses in HBV, especially in those patients with OBI.
